The effects of tolvaptan treatment and copeptin concentration on renal prognosis in patients with chronic kidney disease or nephrotic syndrome, who have heart failure symptoms. - Tolvaptan treatment in patients with renal involvement and heart failure symptoms in relation to copeptin.

Department of Medicine, Kidney Center, Tokyo Women's Medical University0 个研究点目标入组 50 人开始时间: 2014年8月28日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with any mechanical support (e.g., intraaortic balloon pumping, mechanical ventilation) . 2) Patients who were suspected of having hypovolemia. 3) Patients with hemodynamically significant valvular stenosis. 4) Patients who had a history of acute coronary syndrome within 30 days before enrollment. 5) Patients with active systemic infection. 6) Patients undergoing hemodialysis or anuria. 7) Allergy to tolvaptan or tolvaptan-like compounds (e.g., mozavaptan hydrochloride) . 8) Patients cannot drink sufficient water to satisfy thirst, or does not feel thirsty. 9) Patients with hypernatremia. 10) Patients cannot drink sufficient water to satisfy thirst because of hepatic coma. 11) Patients with pregnant or who have possibility of pregnancy. 12) Patients diagnosed with autosomal dominant polycystic kidney disease. 13) Other medical condition unacceptable for entry.

发起方

Department of Medicine, Kidney Center, Tokyo Women's Medical University